Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2018-01-02 | 2017-12-19 |
| Drug Identification Number | 02194376 | 02194376 |
| Brand name | IMMUCYST | IMMUCYST |
| Common or Proper name | Bacillus Calmette-Guérin (BCG), substrain Connaught | Bacillus Calmette-Guérin (BCG), substrain Connaught |
| Company Name | SANOFI PASTEUR LIMITED | SANOFI PASTEUR LIMITED |
| Ingredients | BACILLUS CALMETTE-GUERIN | BACILLUS CALMETTE-GUERIN |
| Strength(s) | 81MG | 81MG |
| Dosage form(s) | POWDER FOR SUSPENSION | POWDER FOR SUSPENSION |
| Route of administration | INTRAVESICAL | INTRAVESICAL |
| Packaging size | 1 x 81 mg vial (1 Treatment) | 1 x 81 mg vial (1 Treatment) |
| ATC code | L03AX | L03AX |
| ATC description | IMMUNOSTIMULANTS | IMMUNOSTIMULANTS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2018-01-01 | 2018-01-01 |
| Actual discontinuation date | 2018-01-01 | 2018-01-01 |
| Remaining supply date | 2017-12-31 | 2017-12-31 |
| Discontinuation status | Discontinued | To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | The production of IMMUCYST® has been discontinued and supply to the Canadian market will be discontinued as of January 01, 2018. | The production of IMMUCYST® has been discontinued and supply to the Canadian market will be discontinued as of January 01, 2018. |
| Health Canada comments |